Do analysts recommend IBAC or BNGO?

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 341.18%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, IBAC or BNGO?

IB Acquisition has higher earnings, but lower revenue than Bionano Genomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Bionano Genomics $28.51M 0.56 -$26.40M -$3.02 N/A

Do analysts prefer BNGO or BFRG?

Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 341.18%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BNGO or BFRG more profitable?

Bullfrog AI has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bionano Genomics -106.58% -78.78% -48.54% Bullfrog AI N/A -150.36% -127.98%

Do analysts prefer VIVS or BNGO?

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 341.18%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VIVS or BNGO more profitable?

Bionano Genomics has a net margin of -106.58% compared to VivoSim Labs' net margin of -11,016.07%. Bionano Genomics' return on equity of -78.78% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -11,016.07% -612.23% -177.02% Bionano Genomics -106.58% -78.78% -48.54%

Bionano Genomics (BNGO) Competitors

$1.37 +0.01 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+0.73%)

As of 07:30 PM Eastern

Compare

BNGO vs. IBAC, RPID, HBIO, BFRG, and VIVS

Should you buy Bionano Genomics stock or one of its competitors? Bionano Genomics's main competitors and comparable companies include IB Acquisition (IBAC), Rapid Micro Biosystems (RPID), Harvard Bioscience (HBIO), Bullfrog AI (BFRG), and VivoSim Labs (VIVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bionano Genomics compare to IB Acquisition?

IB Acquisition (NASDAQ:IBAC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, IB Acquisition and IB Acquisition both had 2 articles in the media. Bionano Genomics' average media sentiment score of 0.41 beat IB Acquisition's score of 0.39 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Overall Sentiment
IB Acquisition	Neutral
Bionano Genomics	Neutral

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 341.18%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IB Acquisition has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. IB Acquisition's return on equity of 0.00% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Bionano Genomics	-106.58%	-78.78%	-48.54%

11.4% of Bionano Genomics shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

IB Acquisition has higher earnings, but lower revenue than Bionano Genomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Bionano Genomics	$28.51M	0.56	-$26.40M	-$3.02	N/A

Summary

Bionano Genomics beats IB Acquisition on 7 of the 10 factors compared between the two stocks.

How does Bionano Genomics compare to Rapid Micro Biosystems?

Rapid Micro Biosystems (NASDAQ:RPID) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Rapid Micro Biosystems has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

In the previous week, Bionano Genomics had 1 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 2 mentions for Bionano Genomics and 1 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 0.86 beat Bionano Genomics' score of 0.41 indicating that Rapid Micro Biosystems is being referred to more favorably in the media.

Company	Overall Sentiment
Rapid Micro Biosystems	Positive
Bionano Genomics	Neutral

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bionano Genomics has a net margin of -106.58% compared to Rapid Micro Biosystems' net margin of -145.56%. Bionano Genomics' return on equity of -78.78% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Bionano Genomics	-106.58%	-78.78%	-48.54%

Rapid Micro Biosystems currently has a consensus target price of $5.00, indicating a potential upside of 472.21%. Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 341.18%. Given Rapid Micro Biosystems' stronger consensus rating and higher possible upside, equities analysts clearly believe Rapid Micro Biosystems is more favorable than Bionano Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bionano Genomics has lower revenue, but higher earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59M	1.30	-$47.12M	-$1.12	N/A
Bionano Genomics	$28.51M	0.56	-$26.40M	-$3.02	N/A

Summary

Rapid Micro Biosystems beats Bionano Genomics on 10 of the 17 factors compared between the two stocks.

How does Bionano Genomics compare to Harvard Bioscience?

Bionano Genomics (NASDAQ:BNGO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bionano Genomics presently has a consensus target price of $6.00, suggesting a potential upside of 341.18%. Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 18.38%. Given Bionano Genomics' higher probable upside, equities analysts clearly believe Bionano Genomics is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Harvard Bioscience has a net margin of -11.86% compared to Bionano Genomics' net margin of -106.58%. Harvard Bioscience's return on equity of -33.13% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Bionano Genomics has higher earnings, but lower revenue than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.56	-$26.40M	-$3.02	N/A
Harvard Bioscience	$86.55M	0.43	-$56.70M	-$2.31	N/A

In the previous week, Bionano Genomics had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 2 mentions for Bionano Genomics and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.61 beat Bionano Genomics' score of 0.41 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Bionano Genomics	Neutral
Harvard Bioscience	Positive

Bionano Genomics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Summary

Harvard Bioscience beats Bionano Genomics on 8 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to Bullfrog AI?

Bionano Genomics (NASDAQ:BNGO) and Bullfrog AI (NASDAQ:BFRG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 341.18%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 14.7% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bullfrog AI has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Bullfrog AI	N/A	-150.36%	-127.98%

Bionano Genomics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.73, meaning that its stock price is 373% less volatile than the broader market.

In the previous week, Bullfrog AI had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 3 mentions for Bullfrog AI and 2 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 0.41 beat Bullfrog AI's score of -0.10 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Overall Sentiment
Bionano Genomics	Neutral
Bullfrog AI	Neutral

Bullfrog AI has lower revenue, but higher earnings than Bionano Genomics. Bullfrog AI is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.56	-$26.40M	-$3.02	N/A
Bullfrog AI	$120K	87.90	-$6.50M	-$0.46	N/A

Summary

Bionano Genomics beats Bullfrog AI on 10 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to VivoSim Labs?

VivoSim Labs (NASDAQ:VIVS) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by insiders. Comparatively, 0.7% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

VivoSim Labs has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	22.23	-$13.84M	-$4.47	N/A
Bionano Genomics	$28.51M	0.56	-$26.40M	-$3.02	N/A

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 341.18%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, VivoSim Labs had 2 more articles in the media than Bionano Genomics. MarketBeat recorded 4 mentions for VivoSim Labs and 2 mentions for Bionano Genomics. VivoSim Labs' average media sentiment score of 0.90 beat Bionano Genomics' score of 0.41 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Positive
Bionano Genomics	Neutral

Bionano Genomics has a net margin of -106.58% compared to VivoSim Labs' net margin of -11,016.07%. Bionano Genomics' return on equity of -78.78% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-11,016.07%	-612.23%	-177.02%
Bionano Genomics	-106.58%	-78.78%	-48.54%

VivoSim Labs has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Summary

Bionano Genomics beats VivoSim Labs on 10 of the 15 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.02M	$10.57B	$7.18B	$13.18B
Dividend Yield	N/A	1.45%	2.52%	19.60%
P/E Ratio	-0.45	20.93	195.97	18.94
Price / Sales	0.57	103.76	564.50	78.56
Price / Cash	N/A	27.31	76.68	52.75
Price / Book	0.31	6.08	10.51	5.92
Net Income	-$26.40M	$56.67B	$3.50B	$380.90M
7 Day Performance	-6.16%	-3.26%	-4.32%	-4.38%
1 Month Performance	3.01%	4.53%	-8.64%	-7.25%
1 Year Performance	-34.45%	24.62%	2.05%	-4.95%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	2.6124 of 5 stars	$1.37 +0.7%	$6.00 +338.0%	-30.6%	$16.02M	$28.51M	N/A	97	Short Interest Increase
IBAC IB Acquisition	N/A	$10.93 +0.4%	N/A	+4.4%	$54.73M	N/A	N/A	2
RPID Rapid Micro Biosystems	3.5667 of 5 stars	$0.98 +0.4%	$5.00 +410.2%	-75.0%	$49.16M	$33.59M	N/A	171	Gap Down
HBIO Harvard Bioscience	1.5212 of 5 stars	$8.65 +1.8%	$6.75 -22.0%	+96.1%	$39.36M	$86.55M	N/A	339	Positive News
BFRG Bullfrog AI	1.5922 of 5 stars	$0.62 +4.9%	N/A	-61.8%	$12.03M	$120K	N/A	17	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. IBAC, RPID, HBIO, BFRG, and VIVS

How does Bionano Genomics compare to IB Acquisition?

Summary

How does Bionano Genomics compare to Rapid Micro Biosystems?

Summary

How does Bionano Genomics compare to Harvard Bioscience?

Summary

How does Bionano Genomics compare to Bullfrog AI?

Summary

How does Bionano Genomics compare to VivoSim Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. IBAC, RPID, HBIO, BFRG, and VIVS

How does Bionano Genomics compare to IB Acquisition?

Does the media refer more to IBAC or BNGO?

Do analysts recommend IBAC or BNGO?

Is IBAC or BNGO more profitable?

Do institutionals & insiders have more ownership in IBAC or BNGO?

Which has stronger earnings & valuation, IBAC or BNGO?

Summary

How does Bionano Genomics compare to Rapid Micro Biosystems?

Which has more risk & volatility, RPID or BNGO?

Does the media favor RPID or BNGO?

Do insiders and institutionals have more ownership in RPID or BNGO?

Is RPID or BNGO more profitable?

Do analysts rate RPID or BNGO?

Which has higher valuation and earnings, RPID or BNGO?

Summary

How does Bionano Genomics compare to Harvard Bioscience?

Do institutionals & insiders believe in BNGO or HBIO?

Do analysts recommend BNGO or HBIO?

Is BNGO or HBIO more profitable?

Which has stronger valuation and earnings, BNGO or HBIO?

Does the media refer more to BNGO or HBIO?

Which has more risk & volatility, BNGO or HBIO?

Summary

How does Bionano Genomics compare to Bullfrog AI?

Do analysts prefer BNGO or BFRG?

Do institutionals & insiders believe in BNGO or BFRG?

Is BNGO or BFRG more profitable?

Which has more risk & volatility, BNGO or BFRG?

Does the media refer more to BNGO or BFRG?

Which has higher earnings and valuation, BNGO or BFRG?

Summary

How does Bionano Genomics compare to VivoSim Labs?

Do insiders & institutionals have more ownership in VIVS or BNGO?

Which has stronger valuation & earnings, VIVS or BNGO?

Do analysts prefer VIVS or BNGO?

Does the media refer more to VIVS or BNGO?

Is VIVS or BNGO more profitable?

Which has more volatility & risk, VIVS or BNGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools